Skip to main content
SpringerLink
Log in

A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Dacarbazine (DTIC) is a chemotherapy drug which has antitumor activity at standard doses, exhibits a steep dose-response effect in vitro, and is associated with relatively few non-hematologic toxicities. These characteristics suggest a potential role for this drug in bone marrow transplant preparative regimens. To pursue this hypothesis, 16 patients with refractory solid tumors were enrolled in a phase I study of single agent DTIC to determine the dose of DTIC requiring bone marrow reinfusion and to define the dose-limiting toxicity and maximum tolerated dose when given with autologous bone marrow rescue. Pharmacokinetics were evaluated at the 4394 mg/m2 dose level. The marrow requiring dose was 2000 mg/m2 when given as a single intravenous (IV) infusion. The extramyeloid dose-limiting toxicity of DTIC was hypotension, with the maximum tolerated dose of DTIC being 3380 mg/m2 when given with bone marrow transplantation (BMT). Other toxicities were transient and tolerable. At 4394 mg/m2 of DTIC, plasma concentrations declined biexponentially with a terminal half-life of 3 hours. The mean clearance was 10.6 L/hr/m2 with a volume of distribution at steady state of 37.5 L/m2 and a mean maximum plasma concentration of 150 mcg/ml. One patient with melanoma developed a partial response of short duration after receiving 2600 mg/m2 of DTIC. Dacarbazine can be significantly dose escalated with an acceptable toxicity profile, when given with BMT. Future trials should focus on the addition of this drug to current BMT preparative regimens used for the treatment of patients with lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cheson BD, Lacerna L, Leyland-Jones B, Sarosy G, Wittes RE: Autologous bone marrow transplantation: Current status and future directions. Ann Int Med 110:51–65, 1989

    Google Scholar 

  2. Schepartz SA: History and development of DTIC (NSC-45388). Cancer Treat Rep 60:123–124, 1976

    Google Scholar 

  3. Loo T, Luce JK, Jardine JH, Frei III E: Pharmacologic studies of the antitumor agent 5-(dimethyl-traizeno)-im-idazole-4-carboxamide. Cancer Res 28:2448–2453, 1968

    Google Scholar 

  4. Bone VH Jr: Studies on the mechanism of action of DTIC (NSC-45388). Cancer Treat Rep 60:141–148, 1976

    Google Scholar 

  5. Loo TL, Housholder GE, Gerulath AH, Saunders PH, Farquhar D: Mechanism of action and pharmacology studies with DTIC (NSC-45388). Cancer Treat Rep 60: 149–152, 1976

    Google Scholar 

  6. Luce JK, Thurman WG, Isaacs BL, Talley RW: Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide. Cancer Chemother Rep 54:119–124, 1970

    Google Scholar 

  7. Moore GE, Meiselbaugh D: DTIC (NSC-45388) toxicity. Cancer Treat Rep 60:219, 1976

    Google Scholar 

  8. Buesa JM, Gracia M, Valle M, Estrada E, Hidalgo OF, Acave AJ: Phase I trial of intermittent high-dose dacarbazine. Cancer Treat Rep 68:499–504, 1984

    Google Scholar 

  9. Harman G, Tweedy W, Craig J, Von Hoff DD: Phase I–II evaluation of DTIC in the treatment of malignant melanoma on a single dose schedule. (Abstract) European Organization for Research and Treatment of Cancer, March, 1989

  10. Moertel CG, Reitermeier RJ, Hahn RG, Schutt AJ: Study of 5- (3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in patients with gastrointestinal cancer. Cancer Chemother Rep 54:471–473, 1970

    Google Scholar 

  11. Venditti JM: Antitumor activity of DTIC (NSC-45388) in animals. Cancer Treat Rep 60:135–140, 1976

    Google Scholar 

  12. Montgomery JA: Experimental studies at Southern Research Institute with DTIC (NSC-45388). Cancer Treat Rep 60:125–134, 1976

    Google Scholar 

  13. Shealy YF, Montgomery JA, Laster WR: Antitumor activity of triazenoimidazoles. Biochem Pharmacol 11:674–676, 1962

    Google Scholar 

  14. Frei E, Luce JK, Talley RW, Vaitkevicius VK, Wilson HE: 5-(3,3-Dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma. Cancer Chemother Rep 56:667–670, 1972

    Google Scholar 

  15. Bonadonna G, Zucali R, Monfardini S, DeLena M, Uslenghi C: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 36:252–259, 1975

    Google Scholar 

  16. Bonadonna G, Valagussa P, Santoro A: Alternating noncross-resistant combination chemotherapy or MOPP in Stage IV Hodgkin's disease: A report of 8-year results. Ann Int Med 104:739–746, 1986

    Google Scholar 

  17. Comis RL: DTIC (NSC-45388) in malignant melanoma: A perspective. Cancer Treat Rep 60:165–176, 1976

    Google Scholar 

  18. Gottlieb JA, Benjamin RS, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, Rivkin SE, Bodey GP, Rodriguez V, Blumenschein GR, Saiki JH, Coltman C, Burgess MA, Sullivan P, Thigpen T, Bottomley R, Balcerzak S, Moon TE: Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 60:199–203, 1976

    Google Scholar 

  19. Vogel CL, Primock A, Owor R, Kyalwazi SK: Effective treatment of Kaposi's sarcoma with 5(3,3-di-methyl-1-trio zona)imidazole-4-carboxamidemethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). Cancer Chemother Rep 57: 65–71, 1973

    Google Scholar 

  20. Kessinger A, Foley JF, Lemon HM: Therapy of malignant APUD cell tumors: effectiveness of DTIC. Cancer 51: 790–794, 1983

    Google Scholar 

  21. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR: Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann Int Med 109:267–273, 1988

    Google Scholar 

  22. Altimari AF, Badrinath K, Reisel HJ, Prinz RA: DTIC therapy in patients with malignant intra-abdominal neuroendocrine tumors. Surgery 102:1009–1017, 1987

    Google Scholar 

  23. Eyre HJ, Eltringham JR, Gehan EA, Vogel FS, Al-Sarraf M, Talley RW, Costanzi JJ, Athens JW, Dishi N, Fletcher WS: Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: a Southwest Oncology Group study. Cancer Treat Rep 70:1085–1090, 1986

    Google Scholar 

  24. English D, Lamberson R, Graves V, Akard LP, McCarthy J, Jansen J: Semiautomated processin of bone marrow grafts for transplantation. Transfusion 29:12–16, 1989

    Google Scholar 

  25. Tate PS, Briele HA: Reversed-phase high-performance liquid chromatography of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxide and metabolites. J Chromatogr 374: 421–424, 1986

    Google Scholar 

  26. Constanzi JJ: DTIC (NSC-45388) studies in the Southwest Oncology Group. Cancer Treat Rep 60:189–192, 1976

    Google Scholar 

  27. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast Jr RC, Gilbert CJ, Oette DH: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318:869–876, 1988

    Google Scholar 

  28. Buesa JM, Mouridsen HT, Van Dosterom AT, Verweij J, Wagner T, Steward W, Poveda A, Vestlev PM, Thomas D, Sylvester R: High-dose DTIC in advanced soft tissue sarcomas in the adult: A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann of Oncol 2:307–309, 1991

    Google Scholar 

  29. Bunker JP, Bendixen HH, Murphy AJ: Hemodynamic effects of intravenously administered sodium citrate. N Eng J Med 266:372–377, 1962

    Google Scholar 

  30. Johnson RO, Metter G, Wilson W, Hill G, Krementz E: Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. Cancer Treat Rep 60:183–187, 1976

    Google Scholar 

  31. Cowan DH, Bergsagel DE: Intermittent treatment of metastatic malignant melanoma with high-dose 5- (3,3-di-methyl-1-triazono) imidazole-4-carboxymide (NSC-45388). Cancer Chemother Rep 55:175–181, 1971

    Google Scholar 

  32. Erichsen C, Jönsson PE: Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma. J Surg Oncol 27:268–270, 1984

    Google Scholar 

  33. Paschke R, Heine M: Pathophysiological aspects of dacarbazine-induced human liver damage. Hepato-gastroenterol 32:273–275, 1985

    Google Scholar 

  34. Houghton AN, Shafi N, Rickles FR: Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease. Cancer 44:2324–2329, 1979

    Google Scholar 

  35. Runne V, Doepfmer K, Antz H, Groth W, Feaux de Lacroix W: Budd-Chiari-Syndrome unter dacarbazin. Deutsche Med Wochenschr 15:230–233, 1980

    Google Scholar 

  36. Frosch PJ, Czarnetzki BM, Macher E, Grundmann E, Gottchalk I: Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma. J Cancer Res Clin Oncol 95:281–286, 1976

    Google Scholar 

  37. Buesa JM, Urrechaga E: Clinical pharmacokinetics of high-dose DTIC. Cancer Chemo Pharmacol 28:475–479, 1991

    Google Scholar 

  38. Breithaupt H, Dammann A, Aigner K: Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. Cancer Chemother Pharmacol 9:103–109, 1982

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Health Science Center at San Antonio, USA

    Douglas R. Adkins (Assistant Professor of Medicine), Rebecca Irvin, John Kuhn, David H. Boldt, G. David Roodman, Donna Salzman, Cesar Freytes, D. D. Von Hoff & C. F. LeMaistre

  2. Audie Murphy VA Hospital, San Antonio, TX, USA

    Douglas R. Adkins (Assistant Professor of Medicine), Rebecca Irvin, John Kuhn, David H. Boldt, G. David Roodman, Donna Salzman, Cesar Freytes, D. D. Von Hoff & C. F. LeMaistre

Authors
  1. Douglas R. Adkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rebecca Irvin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David H. Boldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. David Roodman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Donna Salzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cesar Freytes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. D. Von Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. F. LeMaistre
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adkins, D.R., Irvin, R., Kuhn, J. et al. A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. Invest New Drugs 11, 169–179 (1993). https://doi.org/10.1007/BF00874151

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00874151

Key words

Search

Navigation